Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
Methodological detailssystematic literature research, international expert and patient consensus process, update of a previous consensus document
- Systematic literature research
- International expert and patient consensus process
- Update of a previous consensus document
Scope
As issued by the authors
IL-6 pathway inhibitors (anti-IL-6Rα antibodies and direct IL-6 inhibitors) in immune-mediated inflammatory disease: dosing and populations for approved indications (RA, polyarticular-course and sJIA, GCA, TAK, AOSD, Castleman's disease, CAR-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder, severe COVID-19), and pretreatment screening, safety, contraindications and monitoring
Original publication
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis. Published 11 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →